Ubs Group Ag Nrx Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.29 - $0.7 $8,777 - $21,186	-30,266 Reduced 64.62%	16,571 $7,000
Q4 2023 Feb 09, 2024	BUY	$0.26 - $0.47 $11,863 - $21,444	45,627 Added 3770.83%	46,837 $21,000
Q3 2023 Nov 09, 2023	SELL	$0.23 - $0.5 $356 - $774	-1,548 Reduced 56.13%	1,210 $0
Q2 2023 Aug 11, 2023	SELL	$0.46 - $0.89 $7,292 - $14,109	-15,853 Reduced 85.18%	2,758 $1,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.4 $12,025 - $25,509	18,221 Added 4672.05%	18,611 $12,000
Q4 2022 Feb 08, 2023	BUY	$0.79 - $9.19 $308 - $3,584	390 New	390 $0
Q2 2022 Aug 10, 2022	BUY	$0.51 - $2.42 $6,258 - $29,695	12,271 Added 271.06%	16,798 $10,000
Q1 2022 May 16, 2022	SELL	$2.45 - $5.04 $17,676 - $36,363	-7,215 Reduced 61.45%	4,527 $11,000
Q4 2021 Feb 14, 2022	BUY	$4.5 - $11.91 $52,839 - $139,847	11,742 New	11,742 $56,000
Q3 2021 Nov 15, 2021	SELL	$8.52 - $24.77 $71,440 - $207,696	-8,385 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$11.62 - $44.5 $97,433 - $373,132	8,385 New	8,385 $97,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $81.2M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.